LABIXTEN

This brand name is authorized in Hong Kong, New Zealand

Active ingredients

The drug LABIXTEN contains one active pharmaceutical ingredient (API):

1 Bilastine
UNII PA1123N395 - BILASTINE

Bilastine is a non-sedating, long-acting histamine antagonist with selective peripheral Η1 receptor antagonist affinity and no affinity for muscarinic receptors.

Read about Bilastine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R06AX29 Bilastine R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX29

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HK Department of Health Drug Office Identifier(s): 63485, 66118, 66346
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 18760

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈